Myovant Accepts Higher Sumitovant Offer In Deal That Values It At $2.9bn

Women’s Health, Prostate Cancer Assets To Get A Boost

 
• By Mandy Jackson
Big fish eats smaller fish
Sumitomo subsidiary Sumitovant is buying the remaining shares of Myovant • Source: Shutterstock

More from Deals

More from Business